Gen-hong H. Di
270 Dong An Road
Shanghai, 200032, China
Shanghai, 200032, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 67 publications
ASO Visual Abstract: Omission of Axillary Surgery in Patients with Negative Axillary Evaluation Integrated with LymphPET: A Prospective Clinical Study.
Journal: Annals of surgical oncology
Published: March 30, 2026
Phase separation of DDHD2 remodels lipid metabolism to dictate treatment sensitivity in luminal breast cancer.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: March 11, 2026
Precision neoadjuvant treatment with AI-assisted subtyping in HR+/HER2-breast cancer: A randomized, phase 2 trial FASCINATE-N.
Journal: Cell reports. Medicine
Published: February 04, 2026
Integrated genomic profiling identifies predictive biomarkers for neoadjuvant therapy response in Chinese breast cancer patients.
Journal: Cancer letters
Published: February 03, 2026
Effect of adjuvant carboplatin intensified chemotherapy versus standard chemotherapy on survival in women with high risk, early stage, triple negative breast cancer (CITRINE): randomised, open label phase 3 trial.
Journal: BMJ (Clinical research ed.)
Published: December 23, 2025
Integrated multi-regional multiomic profiling of breast phyllodes tumours reveals peritumoural immune activation and stromal remodelling.
Journal: Clinical and translational medicine
Published: December 14, 2025
Omission of Axillary Surgery in Patients with Negative Axillary Evaluation Integrated with LymphPET: A Prospective Clinical Study.
Journal: Annals of surgical oncology
Published: October 30, 2025
Spatially interpretable artificial intelligence framework to tailored neoadjuvant dual HER2 blockade in HER2-positive breast cancer.
Journal: Signal transduction and targeted therapy
Published: October 19, 2025
CD8-guided immunochemotherapy improves pathological complete response rates in high-tumor-burden triple-negative breast cancer.
Journal: Molecular therapy : the journal of the American Society of Gene Therapy
Published: May 14, 2025
Sitravatinib plus tislelizumab in locally recurrent or metastatic triple-negative breast cancer: a multi-cohort, single-arm, phase II clinical trial (SPARK Trial).
Journal: Molecular cancer
Published: April 28, 2025
TBKBP1 induces capecitabine resistance through negative regulation of type I interferon pathway in triple-negative breast cancer.
Journal: Oncogene
Published: March 04, 2025
Last Updated: 09/26/2026